Lacidipin Teva (Lacidipine)

Lacidipine blocks L‑type calcium channels in vascular smooth muscle, preventing calcium entry that triggers contraction. This causes relaxation of arterial walls, vasodilation, and a reduction in peripheral resistance, which lowers systemic blood pressure.

The dosage of lacidipine is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. The prescriber determines the appropriate strength and dosing schedule.

The safety of lacidipine during pregnancy and lactation has not been established. It is generally classified as contraindicated or used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lacidipin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with other calcium‑channel blockers, lacidipine has a long‑acting profile and high lipophilicity, providing sustained blood‑pressure control. Unlike ACE inhibitors or beta‑blockers, it primarily acts on vascular smooth muscle without significant effects on heart rate, making it suitable for patients who need vasodilation without negative inotropic impact.

Lacidipin tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in humid areas such as bathrooms, and keep out of reach of children.

Lacidipin is taken orally, usually with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the prescriber’s instructions regarding timing and any dietary considerations.

The most serious adverse events include severe hypotension, myocardial infarction, hepatic dysfunction, angioedema, and life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, severe swelling, or rash.

Lacidipine is contraindicated in patients with known hypersensitivity to the drug or other calcium‑channel blockers, in those with severe aortic stenosis, and in individuals with uncontrolled heart failure. Caution is also advised for patients with significant liver impairment or those taking interacting medications.